The timing of use of anthracyclines in induction chemotherapy for acute promyelocytic leukemia

The timing of cytotoxic agents in induction chemotherapy for acute promyelocytic leukemia and their effects on c-reactive protein, interleukin-6, tumor necrosis factor alpha, and early prognosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900025875

Enrollment

Unknown

Registered

2019-09-12

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Promyelocytic Leukemia

Interventions

A group:add cytotoxic drugs such as anthracyclines when WBC =10×10^9/L

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. It conforms to the diagnostic criteria of APL in China's guidelines for diagnosis and treatment of acute promyelocytic leukemia (2018 edition). 2. APL was diagnosed for the first time. 3. The risk stratification in the low-middle risk group was consistent with the WBC (peripheral blood white blood cell count) <10x10^9/L before induction therapy. 4. Aged 14 to 75 years; 5. Double induction therapy with ATRA+ATO.

Exclusion criteria

Exclusion criteria: 1. Death or termination of treatment within 3 days of induction therapy; 2. Intolerance to ARTA, ATO or anthracycline; 3. With serious cardiopulmonary insufficiency; 4. Patients with the second tumor.

Design outcomes

Primary

Measure	Time frame
c-reactive protein;interleukin-6;tumor necrosis factor alpha;gene;	—

Countries

China

Contacts

Public ContactXu Fang

Mianyang Central Hospital

147377807@qq.com+86 13778138821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026